

Parexel appoints Peyton Howell as Chief Operating and Growth Officer

16 September 2022 | News

Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence



Parexel, a leading global clinical research organization (CRO), announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.

As Chief Operating and Growth Officer, Howell will lead Parexel's operational delivery, strategy and growth. She joined Parexel in May 2018 and most recently was President, Consulting and Chief Commercial & Strategy Officer, leading the company to record new business growth and the creation of a patient-focussed strategy.

In addition to providing strategic oversight for the rebranding of Parexel in 2019, Howell was a key architect in the launch of the organisation's new Business Strategy and has consistently led Parexel's global Biotech and Enterprise Commercial teams to record new business growth.

As Chief Medical Officer and Global Head, Oncology Center of Excellence, Dr McKee will provide patient-focused medical and scientific leadership globally in support of the company's Phase I to IV clinical trials. With nearly 20 years of FDA regulatory, clinical research, bench science and clinical medicine experience, she will provide strategic oversight for the company's therapeutic/medical and scientific centres of excellence to drive growth and innovation, including collaboration with key stakeholders to strengthen Parexel as a collaborative drug development partner and establish market-leading, patient-centred teams.